API CDMO Manufacturing: End-to-End Contract API Development & Production
From milligram-scale synthesis to multi-tonne commercial production — US FDA, EU GMP, PMDA, TGA & ANVISA approved API CDMO partner for regulated markets worldwide.
Shilpa Pharma is a globally trusted API CDMO manufacturing partner in India, delivering integrated contract API development and manufacturing services to pharmaceutical innovators, biotech companies, and generic drug developers across North America, Europe, Japan, Australia, and emerging markets. Our cGMP-compliant API manufacturing facilities, approved by seven major regulatory authorities — provide complete API lifecycle support: from early-stage route scouting and process development through clinical manufacturing, scale-up, and long-term commercial supply. With specialized expertise in small molecule APIs, oncology active pharmaceutical ingredients, HPAPIs, and complex chemistries, we combine world-class infrastructure with cost-competitive Indian manufacturing to deliver APIs that consistently meet and exceed international quality standards.
Global Regulatory Approvals: API Manufacturing Certified for Every Major Regulated Market
When choosing an API CDMO partner, regulatory approval history is the single most critical factor. Shilpa Pharma’s manufacturing facilities hold certifications from seven major international regulatory authorities — ensuring that every API we manufacture is accepted in the most demanding regulated markets globally.
Comprehensive API CDMO Capabilities at Shilpa Pharma
API Process Development
Our process chemistry team delivers robust, scalable, and IP-secure synthesis routes tailored to your molecule and target market timeline. Key services include:
- Route scouting and feasibility studies
- Process development and optimization (DoE, QbD)
- Impurity profiling and control strategy development
- Polymorph screening and solid-state characterization
- Chiral resolution and asymmetric synthesis
- Genotoxic impurity (GTI) assessment and control
- Solvent recovery and green chemistry integration
- Technology transfer from research to GMP
cGMP API Manufacturing — From Clinical to Commercial
Shilpa Pharma’s cGMP-compliant API manufacturing infrastructure is designed for flexibility, scalability, and regulatory readiness across every phase of drug development:
| Phase | Scope & Output |
|---|---|
| Pre-Clinical | Gram to 100g scale; route confirmation, process proof-of-concept |
| Phase I / II Clinical | Kilogram scale; GMP batches, impurity profiling, stability initiation |
| Phase III Clinical | Multi-kilogram; optimized process, regulatory package preparation |
| Commercial Scale-Up | Tonne-scale; validated processes, full regulatory submissions, QA review |
| Post-Approval | Continuous supply, process improvements, life-cycle management |
Advanced & Specialty Chemistry Capabilities
What sets Shilpa Pharma apart as an API CDMO partner is our depth of chemistry expertise. We handle reactions and conditions that many contract manufacturers cannot, enabling partners to access complex APIs from a single, trusted source:
| Chemistry / Reaction Type | Chemistry / Reaction Type |
|---|---|
| Asymmetric synthesis & chiral resolution | Continuous flow chemistry (scalable) |
| Cryogenic reactions (down to -90°C) | Hydrogenation (including asymmetric) |
| High-pressure reactions (Pd/Ru/Rh catalysis) | Grignard & organometallic reactions |
| Electrochemical reactions | Boron chemistry |
| Nucleoside & purine chemistry | Pyrimidine & pyridine chemistry |
| Steroid chemistry | Cyclopropane & indole chemistry |
| Enzymatic reactions | Butyl lithium reactions |
| Bromination / chlorination / cyanation | Cytotoxic (oncology) with isolators |
Oncology API & High Potent API (HPAPI) Contract Manufacturing
Shilpa Pharma is one of the few API CDMOs in the world with deep, proven expertise in oncology APIs and high-potency active pharmaceutical ingredients (HPAPIs) — molecules that are effective at extremely low doses but require specialized containment, handling, and manufacturing controls.
H3: Our HPAPI API CDMO Manufacturing Infrastructure
- Dedicated HPAPI manufacturing suites with full containment (OEL down to nanogram levels)
- Cytotoxic compound handling with isolators for maximum operator safety
- Continuous environmental monitoring and real-time containment verification
- Specialized analytical capabilities for trace-level impurity detection in HPAPIs
- Full compliance with EMA, FDA, and ICH Q3D/Q3A/Q3B guidelines for HPAPI products
Key Oncology APIs We Manufacture
Shilpa Pharma manufactures 50+ oncology and non-oncology APIs across multiple therapeutic classes, including:
| Oncology | Cardiovascular / CNS | Specialty / Other |
|---|---|---|
| Imatinib Mesylate | Nifedipine | Fingolimod HCl |
| Olaparib (USP/EP) | Edoxaban Tosylate | Dimethyl Fumarate |
| Palbociclib | Phenylephrine HCl | Pirfenidone |
| Bortezomib | Varenicline Tartrate | Ursodeoxycholic Acid |
| Osimertinib | Tranexamic Acid | Prucalopride Succinate |
| Oxaliplatin (USP/EP) | Ruxolitinib Phosphate | Thalidomide |
Contact for End-to-End API CDMO Services in India
Happy Customers
Projects Successfully Completed
Established
PhD Experts Driving R&D Excellence
Team Size
World-Class API Manufacturing Sites
Global Audits Successfully Completed
Comprehensive CDMO Service Offerings
Why Global Pharma Companies Partner with an API CDMO in India
End-to-End CDMO Solutions
From route scouting to GMP manufacturing, we cover every stage of drug development.
State-of-the-Art R&D
Advanced laboratories for formulation, biologics, and peptide research.
Global Quality Standards
GMP-compliant facilities ensuring regulatory-ready production.
Advanced Manufacturing Capabilities
High-potent APIs, continuous flow chemistry, and scalable processes.
Sustainable & Compliant Operations
Environmentally responsible practices with stringent safety protocols.
Trusted by Pharma Innovators
Reliable partnerships delivering complex projects on time and within budget.
Our API Contract Development & Manufacturing Process
Questions & Answers
Our FAQ's
What is API CDMO manufacturing?
API CDMO manufacturing is the outsourced development and production of active pharmaceutical ingredients (APIs) by a specialized Contract Development and Manufacturing Organization. A CDMO provides end-to-end services from process development and clinical manufacturing through to commercial-scale API production, including regulatory filing support.
What makes Shilpa Pharma a reliable API CDMO partner for global markets?
Shilpa Pharma operates cGMP-compliant API manufacturing facilities approved by seven major regulatory authorities — US FDA, EU GMP, PMDA (Japan), TGA (Australia), ANVISA (Brazil), COFEPRIS (Mexico), and KFDA (South Korea). Combined with 100+ PhD scientists, proven scale-up capabilities, and extensive DMF filings, we deliver APIs that meet the most stringent international standards.
Can you handle high-potency APIs (HPAPIs) and oncology APIs?
Yes. Shilpa Pharma has dedicated HPAPI manufacturing infrastructure with full containment suites and isolator-based handling for cytotoxic compounds. We have a broad portfolio of oncology APIs including tyrosine kinase inhibitors, alkylating agents, antimetabolites, and targeted therapy APIs — all manufactured under cGMP with full regulatory documentation.
What scale of API manufacturing can you support?
We support API manufacturing across all development phases — from gram-scale pre-clinical synthesis and multi-kilogram clinical batches (Phase I, II, III) to multi-tonne commercial-scale production. Our facility network is designed for seamless technology transfer and scale-up within the same regulatory framework.
Do you support API DMF filing and regulatory submissions?
Absolutely. Shilpa Pharma provides comprehensive regulatory support including US FDA DMF preparation and filing, European EDMF and CEP (Certificate of Suitability) applications, Japanese Drug Master File (JDMF) support, IMPD preparation, and CTD-format technical dossier compilation. Our regulatory affairs team has experience responding to queries from multiple international regulatory authorities.
What is the difference between a CMO and CDMO for APIs?
A CMO (Contract Manufacturing Organization) typically provides manufacturing services for established processes. A CDMO (Contract Development and Manufacturing Organization) provides both development and manufacturing — including process R&D, scale-up, analytical development, and regulatory support. Shilpa Pharma is a full CDMO, meaning we support you from the earliest development stage through to long-term commercial supply.
Can Shilpa Pharma manufacture APIs for the US and European markets from India?
Yes. Our facilities are directly inspected and approved by the US FDA and EU authorities. APIs manufactured at our India-based facilities are regularly supplied to pharmaceutical companies in the US, EU, UK, Japan, and other regulated markets. Our India-based manufacturing provides significant cost advantages without any compromise on regulatory acceptance or product quality.
How do I initiate a partnership with Shilpa Pharma for API CDMO services?
Contact our business development team via the form on this page or email info@shilpapharma.com. Share your molecule details, development stage, target markets, and timeline requirements. Our technical team will respond within 2 business days with an initial assessment and proposed scope.
Countries We Serve in
Learn About API Contract Manufacturing development globally
API CDMO Manufacturing: End-to-End Contract API Design, Development & Production
At Shilpa Pharma, we offer comprehensive API CDMO (Contract Development and Manufacturing Organization) services, supporting pharmaceutical companies from early-stage development to full-scale commercial production. Our integrated capabilities ensure speed, compliance, and scalability across the entire API lifecycle.
What Is API CDMO Manufacturing?
API CDMO manufacturing refers to the outsourced contract development and manufacturing of Active Pharmaceutical Ingredients (APIs) — the biologically active components in any drug that produce the intended therapeutic effect. A CDMO (Contract Development and Manufacturing Organization) specializing in APIs provides end-to-end support across the entire API lifecycle, including:
- Route scouting & process research — identifying the most efficient, cost-effective synthesis pathway
- API process development & optimization — de-risking scale-up through systematic DoE and quality-by-design
- cGMP manufacturing — from gram-scale clinical batches to multi-tonne commercial production
- Analytical development & method validation — per ICH guidelines
- Regulatory documentation — DMF filing, CEP applications, IMPD preparation
- Technology transfer — seamless handover to internal or third-party sites
Pharmaceutical companies — from emerging biotech to global Big Pharma — partner with API CDMOs to reduce capital expenditure, accelerate development timelines, access specialized chemistry expertise, and ensure regulatory readiness for targeted global markets. Outsourcing API manufacturing to a proven CDMO partner like Shilpa Pharma allows innovators to focus on drug discovery and commercialization while relying on dedicated manufacturing expertise.
Global Regulatory Approvals: API Manufacturing Certified for Every Major Regulated Market
When choosing an API CDMO partner, regulatory approval history is the single most critical factor. Shilpa Pharma’s manufacturing facilities hold certifications from seven major international regulatory authorities — ensuring that every API we manufacture is accepted in the most demanding regulated markets globally.
Authority | Full Name | Market Access |
United States Food & Drug Administration | USA, Canada (by reference) | |
EU GMP | European Union Good Manufacturing Practice | EU-27 + UK, Switzerland, EEA |
PMDA | Pharmaceuticals & Medical Devices Agency | Japan |
TGA | Therapeutic Goods Administration | Australia, New Zealand |
ANVISA | National Health Surveillance Agency | Brazil, LATAM |
COFEPRIS | Federal Commission for Protection Against Sanitary Risk | Mexico, Central America |
Korea Food & Drug Administration | South Korea |
DMF & Regulatory Filing Support
Beyond manufacturing, Shilpa Pharma provides full regulatory documentation support to accelerate your market access:
- US FDA Drug Master File (DMF) preparation and filing
- European Drug Master File (EDMF) and Certificate of Suitability (CEP) applications
- Japanese Drug Master File (JDMF) support
- IMPD (Investigational Medicinal Product Dossier) preparation
- CTD-format technical dossier compilation
- Regulatory response support for deficiency letters
- Annual product review and change management documentation
Why Global Pharma Companies Partner with an API CDMO in India
India has emerged as a premier global hub for API contract development and manufacturing — not because of cost alone, but because of the unique combination of scientific depth, regulatory maturity, and manufacturing excellence that leading Indian CDMOs deliver. Pharmaceutical companies across North America, Europe, and Asia Pacific increasingly choose India-based API CDMOs for the following strategic advantages:
Advantage | What It Means for You |
Cost Competitiveness | 30–50% lower manufacturing costs vs. European or US CDMOs without compromising quality or compliance |
Regulatory-Ready Infrastructure | Multiple USFDA-inspected, EU GMP-certified facilities — products accepted directly in regulated markets |
Scientific Depth | 100+ PhD-level scientists; deep expertise in complex chemistries unavailable at many Western CDMOs |
Supply Chain Resilience | India-based API production reduces dependency on Chinese supply chains — a critical concern for regulated market buyers post-COVID |
Scale Flexibility | Seamless scale-up from clinical to commercial volumes within the same facility network |
DMF Portfolio | Extensive DMF portfolio across multiple territories accelerates your regulatory pathway |
API CDMO Manufacturing Across Therapeutic Areas
Shilpa Pharma has established API manufacturing expertise across the following therapeutic categories:
✓ Oncology & Hematology | ✓ Rare Diseases & Orphan Drugs |
✓ Cardiovascular & Anti-thrombotic | ✓ Central Nervous System (CNS) |
✓ Anti-inflammatory & Immunology | ✓ Antiviral & Infectious Diseases |
✓ Respiratory | ✓ Metabolic & Endocrine Disorders |
Partner With a Trusted CDMO API Manufacturing Company
If you are looking for a dependable CDMO API manufacturing partner, Shilpa Pharma offers the expertise, infrastructure, and flexibility to support your success—from development to commercialization.
Contact us today to explore how our pharma API technology CDMO solutions can accelerate your product journey.
